UNLIMITED TURBO LONG - AMGEN | Delayed Deutsche Boerse AG 13:21:24 24/06/2024 BST | ||
| 9.82 EUR | -1.50% |
|
| Current month | +5.39% | ||
| 1 month | -4.23% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24/06/24 | 9.82 | -1.50% |
| 21/06/24 | 9.97 | +0.30% |
| 20/06/24 | 9.94 | +3.11% |
| 19/06/24 | 9.64 | +1.15% |
| 18/06/24 | 9.53 | +1.82% |
Delayed Quote Deutsche Boerse AG
Last update June 24, 2024 at 01:21 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
BNP Paribas
|
| WKN | PX2DKL |
| ISIN | DE000PX2DKL9 |
| Date issued | 31/07/2019 |
| Strike | 204.8 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.26 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 11.94 € |
|---|---|
| Lowest since issue | 0.58 € |
| Spread | 0.22 € |
| Spread % | 2.20% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
308.2
USD
Average target price
316.4
USD
Spread / Average Target
+2.69%
- Stock Market
- Certificates
- Certificat
